SCHEMBL3200415

SCHEMBL3200415

Oc1ccc2c(c1)COc1c-2cc2ccc(O)cc2c1-c1ccc(Cl)c(Cl)c1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 9/20 0.43
ESR2 Q92731 9/20 0.43
ESRRB O95718 3/20 0.37
ESRRA P11474 3/20 0.37
HSD17B10 Q99714 1/20 0.36
CYP17A1 P05093 2/20 0.33
CYP3A4 P08684 2/20 0.33
CYP11B1 P15538 2/20 0.33
CYP11B2 P19099 2/20 0.33
ALOX5 P09917 1/20 0.33
NPC1 O15118 1/20 0.33
PIK3CD O00329 1/20 0.33
GYS1 P13807 1/20 0.33
PIK3CA P42336 1/20 0.33
PIK3CB P42338 1/20 0.33
PIK3CG P48736 1/20 0.33
MAOA P21397 1/20 0.33
MAOB P27338 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3190566 0.89 ESRRB (0.47) ESR1ESR2ESRRBESRRAHSD17B10
SCHEMBL3195435 0.88 ESRRB (0.39) ESR1ESR2ESRRBESRRAHSD17B10
SCHEMBL3179861 0.86 ESR1 (0.40) ESR1ESR2ESRRBESRRA
SCHEMBL3195539 0.86 ESRRB (0.50) ESRRBESRRACYP17A1CYP3A4CYP11B1
SCHEMBL3191309 0.86 ESR2 (0.41) ESR1ESR2ESRRBESRRA
SCHEMBL3185517 0.85 ESR1 (0.40) ESR1ESR2ESRRBESRRAHSD17B10
SCHEMBL3203612 0.85 ESR1 (0.40) ESR1ESR2ESRRBESRRANPC1
SCHEMBL3188483 0.85 ALOX5 (0.39) ESR1ESR2ESRRBESRRACYP17A1
SCHEMBL3186636 0.83 CYP17A1 (0.38) ESR1ESR2ESRRBESRRACYP17A1
SCHEMBL3193942 0.83 MIF (0.41) ESR1ESR2ESRRBESRRACYP17A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7157492-B2 Dibenzo chromene derivatives and their use as ERβ selective ligands WYETH (US) 2007-01-02 US claimed
EP-1718630-A1 DIBENZO CHROMENE DERIVATIVES AND THEIR USE AS ER&bgr; SELECTIVE LIGANDS Wyeth a Corporation of the State of Delaware (US) 2006-11-08 EP claimed
US-20050234074-A1 Dibenzo chromene derivatives and their use as ERbeta selective ligands WYETH (US) 2005-10-20 US claimed
WO-2005082880-A1 DIBENZO CHROMENE DERIVATIVES AND THEIR USE AS ERβ SELECTIVE LIGANDS WYETH (US) 2005-09-09 WO claimed
US-7671084-B2 Dibenzo chromene derivatives and their use as ERβ selective ligands WYETH (US) 2010-03-02 US disclosed
US-20070049605-A1 Dibenzo chromene derivatives and their use as ERbeta selective ligands WYETH (US) 2007-03-01 US disclosed
US-7157492-B2 Dibenzo chromene derivatives and their use as ERβ selective ligands WYETH (US) 2007-01-02 US disclosed
EP-1718630-A1 DIBENZO CHROMENE DERIVATIVES AND THEIR USE AS ER&bgr; SELECTIVE LIGANDS Wyeth a Corporation of the State of Delaware (US) 2006-11-08 EP disclosed
US-20050234074-A1 Dibenzo chromene derivatives and their use as ERbeta selective ligands WYETH (US) 2005-10-20 US disclosed
WO-2005082880-A1 DIBENZO CHROMENE DERIVATIVES AND THEIR USE AS ERβ SELECTIVE LIGANDS WYETH (US) 2005-09-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234074-A1 Dibenzo chromene derivatives and their use as ERbeta selective ligands ESR2, ESR1, ESRRB ESR1 2/4885ESR2 1/4885ESRRB 3/4885
US-20070049605-A1 Dibenzo chromene derivatives and their use as ERbeta selective ligands ESR2, ESR1, ESRRA ESR1 2/4885ESR2 1/4885ESRRB 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.